Cardiovascular Disease in Columbus, OH
130 verified cardiovascular disease doctors in Columbus. Page 3 of 3.
Cardiologists diagnose and treat conditions of the heart and blood vessels, including heart disease, arrhythmias, and heart failure.
NPPES tenure ≠ clinical experience. "Years on NPPES" is time since the physician first registered a National Provider Identifier, not time practicing medicine. Verify current license status with the state medical board.
Dr. Natee Sirinvaravong, MD
Cardiovascular Disease
CMS Open Payments· $21,729 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$21,729
Total received
56
Transactions
5
Paying companies
Top paying companies
Among the 26,323 cardiovascular disease doctors we've analyzed, about 66% received any industry payment (median $653 among those who did). This doctor's total is higher than 93% of that group — among the highest recipients.
Benchmark reflects doctors we've analyzed, not all US cardiovascular disease doctors.
Payments to Natee Sirinvaravong do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Hatem Mowafy, MD
Cardiovascular Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Chad Hyer, MD
Cardiovascular Disease
CMS Open Payments· $58.95 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$58.95
Total received
4
Transactions
2
Paying companies
Top paying companies
Among the 26,323 cardiovascular disease doctors we've analyzed, about 66% received any industry payment (median $653 among those who did). This doctor's total is on the lower end — around the 42th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US cardiovascular disease doctors.
Payments to Chad Hyer do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Piotr Horbal, DO
Cardiovascular Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Katarzyna Gil, MD
Cardiovascular Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Frank Weigel, DO
Cardiovascular Disease
CMS Open Payments· $32.79 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$32.79
Total received
2
Transactions
2
Paying companies
Top paying companies
Among the 26,323 cardiovascular disease doctors we've analyzed, about 66% received any industry payment (median $653 among those who did). This doctor's total is on the lower end — around the 39th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US cardiovascular disease doctors.
Payments to Frank Weigel do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Alisha Alabre-Bonsu, MD
Cardiovascular Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Edwin Lu, MD
Cardiovascular Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Stephanie Bogin, DO
Cardiovascular Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.